Erlotinib: Small-molecule targeted therapy in the treatmentof non-small-cell lung cancer

For patients with NSCLC in whom1026 more than 1 or 2 previous chemotherapeutic regimens have failed, erlotinib is an effective therapy with significant overall survival benefits. The use of erlotinib as first-line therapy in combination with platinum-based chemotherapeutic regimens, however, has failed to demonstrate efficacy in the treatment of NSCLC.